Among older hypertensive patients with antihypertensive medications, those who had echocardiographically determined cardiac hypertrophy may be at high risk for cognitive dysfunction, irrespective of their office BP and 24-h BP levels.
A 60-year-old man with a history of cerebral infarction presented at our hospital. He was subsequently diagnosed to have multiple liver metastases of advanced descending colon cancer, based on the findings of computed tomography. His physical examination showed hemiplegia of the right upper and lower limbs. He was treated with palliative chemotherapy, consisting of capecitabine, oxaliplatin (XELOX), and bevasizumab. After two cycles of this chemotherapy, handfoot syndrome (HFS) prominently developed in the palm of his left hand (Picture 1). HFS remained for seven days after the onset of symptoms (Picture 2). HFS is the most common toxicity of capecitabine related to the tissue-specific expression of drug-metabolizing enzymes and it is usually seen in both the hands and the feet (1). To our knowledge, this is only the second case of capecitabine-induced unilateral HFS to be reported (2). This report suggests that HFS is strongly linked to the mechanical disturbance of daily life and it may also influence the onset of long-term paralysis.
The authors state that they have no Conflict of Interest (COI).
References
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.